1. Scrip
  2. >>R&D

DzGenes LLC

 
• By Mark Ratner

DzGenes has collected more than 15,000 clinical genomic DNA samples and is using them to find disease-associated single nucleotide polymorphisms.

Academic nephrologist David Moskowitz spent years collecting epidemiologic data in his lab. Analyses of genomic DNA from blood samples taken from his kidney patients consistently showed a link between disease and expression of angiotensin I-converting enzyme (ACE). The observation was subsequently borne out during four years of successfully treating his 1,000 patients with ACE inhibitors, which are normally used to treat hypertension. His experience made Moskowitz a believer in the concept of gene-based drug targets and prompted him to form DzGenes LLC . The company's goal is to find single nucleotide polymorphisms, or SNPs, that are associated with diseases affecting large numbers of patients, such as end-stage renal failure and other complications of hypertension and diabetes, and cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Revolution’s Next KRAS Drug Shows Promise In NSCLC

 
• By Andrew McConaghie

Already a frontrunner in developing the KRAS G12D inhibitor class, analysts think Revolution Medicine could seal its leadership by combining zoldonrasib with other agents in its portfolio.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

GSK: Blenrep’s Return Is Just The Start Of Our Oncology Renaissance

 
• By Andrew McConaghie

GSK’s antibody-drug conjugate looks set for a blockbuster future in multiple myeloma after an approval in the UK, and the company’s head of oncology says it is already planning for the next generation of therapies.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.

More from Scrip

BMS Makes Dealmaking A Top Priority As Doubts About Growth Increase

 
• By Mandy Jackson

Bristol’s CEO Christopher Boerner says business development is the company’s biggest spending priority as analysts raise concerns about growth, citing a need for BMS to do more deals.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 
• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

 
• By Joseph Haas

CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.